HRS 2025: Evolving Strategies in Cardiac Contractility Modulation: Clinical Applications and Practical Approaches
This educational session at HRS 2025, co-moderated by Drs. Bradley Knight and Devi Nair, discussed the clinical evidence and practical applications of CCM® Therapy in heart failure care. Dr. Marat Fudim highlighted persistent gaps in current treatment and emphasized the importance of collaboration between heart failure specialists and electrophysiologists. Dr. Vivek Reddy reviewed the latest data and totality of evidence supporting CCM Therapy. Dr. Niraj Varma discussed the roles of CCM and CRT in the treatment pathway, as well as the potential of future combination approaches that are currently under clinical evaluation. Dr. Ambrose Panico shared real-world insights on identifying appropriate CCM candidates and the therapy’s impact on quality of life and shared a personal case study. An interactive Q&A concluded the session, reinforcing CCM Therapy’s role in treating symptomatic heart failure patients.
CCM Therapy is indicated for patients with heart failure who are classified as NYHA Class III, remain symptomatic despite GDMT, have a left ventricular ejection fraction (LVEF) between 25–45%, and are not eligible for CRT.
Disclaimer: CCM-D, developed by Impulse Dynamics, is an investigational device which is not for sale in the US (or elsewhere). CCM-D is the subject of the ongoing Integra-D clinical research study. Read about the study here: https://impulse-dynamics.com/integra-d-ide/.
